Novo Nordisk continues to invest aggressively in its next-generation obesity pipeline and lifecycle management strategies, setting the stage for an increasingly intense battle for leadership in one of the fastest-growing pharmaceutical markets globally
[DOI] [PubMed] [Google Scholar] 257.Buss W.W., Lemanske R.J., Gern J.E
So when is obesity a chronic recurring disease, and what are the implications of now being able to use that label
According to a 2018 study, TB-500 has strong antioxidant, anti-inflammatory, and antifibrotic properties in the specific context of alcoholic liver injury
Mild digestive symptoms such as nausea or constipation can occur early on, but these typically improve as the body adjusts
To view digital features for this article go to Introduction Obesity (defined as a body mass index [BMI] 30 kg/m 2 in adults [1]) is a major health concern in the USA [2] and is associated with multiple complications, including cardiovascular disease, type 2 diabetes, and osteoarthritis [3,4,5,6,7,8]